miR-504调控蛋白酶体激活因子抑制人乳腺癌细胞系MCF-7增殖及迁移

doi:10.16352/j.issn.1001-6325.2023.01.0095

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (1): 95-101.doi: 10.16352/j.issn.1001-6325.2023.01.0095

miR-504调控蛋白酶体激活因子抑制人乳腺癌细胞系MCF-7增殖及迁移

杨良权^1*, 于淼¹, 姜茜¹, 张明慧¹, 杨海松²

1.秦皇岛市妇幼保健院乳腺外科,河北秦皇岛 066000;
2.贵州医科大学附属医院乳腺外科,贵州贵阳 550004

收稿日期:2021-09-01 修回日期:2022-05-18 发布日期:2022-12-27
通讯作者: ^*ylquan4tb@aliyun.com
基金资助:
秦皇岛市重点研发计划科技支撑项目(202005A028)

miR-504 regulates proteasome activator and inhibits the proliferation and migration of breast cancer cell line MCF-7

YANG Liangquan^1*, YU Miao¹, JIANG Qian¹, ZHANG Minghui¹, YANG Haisong²

1. Department of Galactophore Surgery, Maternal ＆ Child Care Center of Qinhuangdao, Qinhuangdao 066000;
2. Department of Galactophore Surgery, the Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China

Received:2021-09-01 Revised:2022-05-18 Published:2022-12-27
Contact: ^*ylquan4tb@aliyun.com

摘要/Abstract

摘要： 目的观察miR-504在模型裸鼠以及乳腺癌细胞生物学行为的调节作用,寻找miR-504在调控过程中的关键靶基因,探究miR-504在乳腺癌中的调控机制。方法构建乳腺癌模型小鼠并观察miR-504对瘤体生长的影响。TargetScan筛选miR-504的靶基因并通过双荧光素酶报告基因实验证实;RT-qPCR、Western blot检测蛋白酶体激活因子复合体亚基3(PSME3)在乳腺癌组织和癌旁组织中的表达;CCK8法、流式细胞测量术和Transwell小室法检测miR-504和PSME3对人乳腺癌细胞系MCF-7细胞增殖,周期和迁移能力的作用。结果在乳腺癌裸鼠移植瘤模型中miR-504能抑制瘤体生长;PSME3是miR-504的靶基因,在乳腺癌组织的表达明显升高(P<0.01),上调miR-504的表达能抑制PSME3的表达 (P<0.01);较NC组,miR-504 mimic组能抑制乳腺癌细胞增殖、S期阻滞和迁移能力,而较miR-504 mimic组,miR-504 mimic+PSME3组MCF-7细胞增殖、S期比例和迁移能力升高(P<0.01)。结论 miR-504可能通过靶向调控PSME3在乳腺癌中发挥抑癌作用。

关键词: 乳腺癌, miR-504, 蛋白酶体激活因子复合体亚基3, MCF-7细胞, 增殖

Abstract: Objective To observe the regulation of miR-504 in mouse models and the biological behavior of breast cancer cells, find the key target genes of miR-504 in the regulation process, and explore the working mechanism of miR-504 in breast cancer. Methods A mouse model of breast cancer was established and the effect of miR-504 on tumor growth was observed. Target genes of miR-504 were screened by Target Scaning and confirmed by double luciferase reporter gene assay. RT-qPCR and Western blot were used to detect proteasome activator complex subunit 3(PSME3) expression in breast cancer and adjacent tissues. The effects of miR-504 and PSME3 on proliferation, cycle and migration of human breast cancer cell line MCF-7 were determined by CCK8 assay, flow cytometry and Transwell assay. Results It was found that miR-504 inhibited tumor growth in nude mouse xenograft model of breast cancer(P<0.01). PSME3 was a target gene of miR-504, and its expression in breast cancer tissues was significantly increased. Up-regulation of miR-504 expression could inhibit the expression of PSME3 (P<0.01). Compared with NC group, miR-504 mimic group could inhibit the proliferation, S-phase arrest and migration ability of breast cancer cells, while compared with miR-504 mimic group, miR-504 mimic+PSME3 group, increased proliferation the proportion of S-phase and migration ability(P<0.01)in MCF-7 cell. Conclusions miR-504 may play an anti-cancer role in breast cancer by targeting PSME3 regulation.

Key words: breast cancer, miR-504, proteasome activator complex subunit 3, MCF-7 cell, proliferation

中图分类号:

R73-37

杨良权, 于淼, 姜茜, 张明慧, 杨海松. miR-504调控蛋白酶体激活因子抑制人乳腺癌细胞系MCF-7增殖及迁移[J]. 基础医学与临床, 2023, 43(1): 95-101.

YANG Liangquan, YU Miao, JIANG Qian, ZHANG Minghui, YANG Haisong. miR-504 regulates proteasome activator and inhibits the proliferation and migration of breast cancer cell line MCF-7[J]. Basic & Clinical Medicine, 2023, 43(1): 95-101.

参考文献

[1] Fang H, Xie J, Zhang M, et al. miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN[J]. Am J Transl Res, 2017, 9: 953-961.
[2] Zhang HY, Liang F, Zhang JW, et al. Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205[J]. Cancer Chemother Pharmacol, 2017,79:327-337.
[3] Wu S, Huang Y, Tang Q, et al. Quantitative evaluation of redox ratio and collagen characteristics during breast cancer chemotherapy using two-photon intrinsic imaging[J]. Biomed Opt Express, 2018, 9:1375-1388.
[4] Hong H, Yu H, Yuan J, et al. MicroRNA-200b Impacts breast cancer cell migration and Invasion by Regulating Ezrin-Radixin-Moesin[J]. Med Sci Monit, 2016, 22:1946-1952.
[5] Liu X, Guan Y, Wang L, et al. MicroRNA-10b expres-sion in nodenegative breast cancer-correlation with metastasis and angiogenesis[J]. Oncol Lett,2017,14:5845-5852.
[6] Peng F, Xiong L, Tang H, et al. Regulation of epitheliao-mesenchymal transition through microRNAs in breast cancer[J]. Tumour Biol, 2016, 37:14463-14477.
[7] Ye MF, Zhang JG, Guo TX, et al. miR-504 inhibits cell proliferation and invasion by targeting LOXL2 in non small cell lung cancer[J]. Biomed Pharmacother, 2018,97:1289-1295.
[8] Kikkawa N, Kinoshita T, Nohata N, et al. MicroRNA-504 inhibits cancer cell proliferation via targeting CDK6 in hypopharyngeal squamous cell carcinoma[J]. Int J Oncol, 2014,44:2085-2092.
[9] Wang L, Lyu X, Wu F, et al. MicroRNA-504 targets AEG-1 and inhibits cell proliferation and invasion in retinoblastoma[J]. Mol Med Rep, 2019,19:2935-2942.
[10] 王会峰, 赵志军, 王燕,等. 稳定敲除CACYBP/SIP基因的MCF-7细胞株的构建及其细胞增殖的变化[J]. 基础医学与临床, 2019, 39: 1682-1688.
[11] Quan H, Li B, Yang J, et al. MicroRNA-504 functions as a tumor suppressor in hepatocellular carcinoma through inhibiting Frizzled-7-mediated-Wnt/β-catenin signaling[J]. Biomed Pharmacother, 2018,107:754-762.
[12] Song W, Guo C, Chen J, et al. Silencing PSME3 induces colorectal cancer radiosensitivity by downregulating the expression of cyclin B1 and CKD1[J]. Exp Biol Med (Maywood), 2019, 244:1409-1418.
[13] Yu L, Li JJ, Liang XL, et al. PME3 pomotes TGFB1 secretion by pancreatic cancer cells to induce pancreatic stellate cell proliferation[J]. J Cancer, 2019,10:2128-2138.
[14] Yi Z, Yang D, Liao X, et al. PSME3 induces epithelial-mesenchymal transition with inducing the expression of CSC markers and immunosuppression in breast cancer[J]. Exp Cell Res, 2017, 358:87-93.

[1]	王群, 李鑫, 马俊, 李婉明. 核酸适配体W3介导靶向乳腺癌的量子点成像[J]. 基础医学与临床, 2023, 43(1): 76-82.
[2]	贺晶, 李艳, 王延峰, 鲍慧. FABP4表达上调促进人子宫内膜癌细胞系HEC-1-A增殖和迁移[J]. 基础医学与临床, 2022, 42(9): 1356-1361.
[3]	张晓雷, 刘静, 李朝萍. Circ_0032821参与索拉非尼抑制乳腺癌细胞系T47D增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(9): 1350-1354.
[4]	王娟, 张晓燕, 朱爱华, 于宏波, 范新丹, 汤春辉, 姚秀芳. Ku70高表达促进人卵巢癌细胞系的增值并与卵巢癌患者不良预后相关[J]. 基础医学与临床, 2022, 42(9): 1391-1399.
[5]	沈永华, 汪峻峰, 程泽星, 冯娟娟. 秦皮甲素抑制人鼻咽癌细胞系HNE-3增殖[J]. 基础医学与临床, 2022, 42(8): 1237-1242.
[6]	谢思安, 陈奕阳, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 张澍田. PTOV1表达水平对结直肠癌患者预后的影响[J]. 基础医学与临床, 2022, 42(8): 1176-1181.
[7]	江宁, 郭钧, 刘铖, 周举. 莪术醇抑制人骨肉瘤细胞系的增殖和促凋亡[J]. 基础医学与临床, 2022, 42(8): 1200-1205.
[8]	刘磊, 李世宝, 张好良. 沉默lnc-SLC2A12-10:1抑制人胃癌细胞系AGS增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(7): 1071-1076.
[9]	王子辕, 段昭君, 罗云萍. 小鼠乳腺癌肺特异性转移细胞亚系的建立和验证[J]. 基础医学与临床, 2022, 42(7): 1083-1091.
[10]	韩雪莹, 崔丰, 李隽. 乳腺癌缺失因子1(DBC1)影响乳腺癌细胞系对依托泊苷的敏感性[J]. 基础医学与临床, 2022, 42(7): 1060-1066.
[11]	康有力, 赵丹, 杜文静, 李莉. SIRT5通过调控ALDH5A1的琥珀酰化促进人乳腺癌细胞的增殖[J]. 基础医学与临床, 2022, 42(7): 1099-1107.
[12]	白冰, 张海芳, 杨庆良, 秦悦, 周晨龙, 宋歌, 王颖. 下调lncRNA RHPN1-AS1抑制人膀胱癌细胞系T24增殖和迁移[J]. 基础医学与临床, 2022, 42(6): 940-944.
[13]	谢利华, 杨奇, 李雅倩, 谢心悦, 雷诗娟, 周琳. 转录因子Kaiso下调人乳腺癌细胞系中lncRNA MEG3的表达[J]. 基础医学与临床, 2022, 42(5): 758-762.
[14]	孙全鹏, 樊超, 展德玺, 范怡明, 孙伟峰. 罗哌卡因抑制人肝癌细胞系Hep3B增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(3): 448-453.
[15]	张健, 张吉炯. LncRNA UNC5B-AS1靶向miR-339-5p调控人肺腺癌细胞系A549增殖和凋亡[J]. 基础医学与临床, 2022, 42(3): 454-460.

miR-504调控蛋白酶体激活因子抑制人乳腺癌细胞系MCF-7增殖及迁移

miR-504 regulates proteasome activator and inhibits the proliferation and migration of breast cancer cell line MCF-7

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价